Navigation Links
Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
Date:11/2/2010

PITTSBURGH, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

Each year in the United States about 200,000 men are diagnosed with prostate cancer. It is the second most common cancer among men, second only to skin cancer.  Most men with prostate cancer are over age 65, and the disease disproportionately strikes African-American men.

"Any cancer diagnosis can impact quality of life, but a prostate cancer diagnosis can be particularly difficult for men because impotence is a common side effect of treatment," said Russell Fuhrer, MD. "While recent improvements have made loss of potency less common after prostate cancer therapy, men must still take this complication into account as they decide on a treatment plan."

The AGH study, "Preservation of Sexual Function After High-Dose Post Prostatectomy Image Guided Intensity-Modulated Radiation Therapy (IMRT)," looked at 33 patients who underwent prostate removal surgery using open or robotic nerve-sparing techniques, followed by Image Guided IMRT radiotherapy.

Image Guided IMRT is an advanced type of radiotherapy in which computer-controlled linear accelerators direct radiation precisely to the tumor, sparing surrounding healthy tissues. Used extensively to treat prostate cancer, Image guided IMRT allows a higher, more focused and effective dose of radiation to the tumor.

Before radiotherapy, the men assessed their sexual function using a self-administered questionnaire called SHIM, Sexual Health Inventory for Men. For men who qualified as potent, researchers again used the SHIM test to measure their potency after radiotherapy.

Among men in the AGH study who were potent at the beginning of radiation therapy, 71 percent maintained potency at 27 months following radiotherapy with Image guided IMRT.

"These results suggest that men who must undergo radiotherapy following a prostatectomy can be confident that they have an excellent chance of maintaining potency after treatment when Image guided IMRT is used," Dr. Fuhrer said.


'/>"/>
SOURCE West Penn Allegheny Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
2. Allegheny General Hospital Performs First Liver Transplant
3. Accuray Hires General Manager for the Asia Pacific Region
4. General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. North American Spine Partners With University General Hospital to Bring Back Pain Relief to Houston Patients
7. US Oncology Announces Addition of John Osborn as EVP & General Counsel and Asif Ahmad as EVP of Technology Services
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
10. Xacore Partners With ESSE, Headed by Retired Army Four Star General, to Tackle Military Hearing Loss
11. Acuo Technologies Announces Implementation and Acceptance of Acuos DICOM Services Grid(TM) With Lancaster General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):